LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Harvard Bioscience Inc

Закрыт

СекторЗдравоохранение

0.73 -3.95

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

0.72

Макс.

0.76

Ключевые показатели

By Trading Economics

Доход

1.1M

-1.2M

Продажи

141K

21M

Рентабельность продаж

-5.978

Сотрудники

330

EBITDA

1M

1.2M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+163.16% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

8.2M

34M

Предыдущая цена открытия

4.68

Предыдущая цена закрытия

0.73

Новостные настроения

By Acuity

26%

74%

84 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bearish Evidence

Harvard Bioscience Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 дек. 2025 г., 22:02 UTC

Отчет

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 дек. 2025 г., 21:46 UTC

Отчет

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 дек. 2025 г., 23:52 UTC

Приобретения, слияния, поглощения

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 дек. 2025 г., 23:43 UTC

Обсуждения рынка

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 дек. 2025 г., 23:36 UTC

Обсуждения рынка

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 дек. 2025 г., 23:20 UTC

Отчет

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 дек. 2025 г., 23:15 UTC

Отчет

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 дек. 2025 г., 22:59 UTC

Обсуждения рынка
Отчет
Приобретения, слияния, поглощения

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 дек. 2025 г., 22:45 UTC

Обсуждения рынка

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 дек. 2025 г., 22:40 UTC

Отчет

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 дек. 2025 г., 22:06 UTC

Приобретения, слияния, поглощения

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 дек. 2025 г., 22:06 UTC

Отчет

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 дек. 2025 г., 22:02 UTC

Отчет

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 дек. 2025 г., 22:00 UTC

Отчет

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 дек. 2025 г., 21:53 UTC

Отчет

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 дек. 2025 г., 21:50 UTC

Приобретения, слияния, поглощения

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 дек. 2025 г., 21:50 UTC

Обсуждения рынка
Отчет
Приобретения, слияния, поглощения

Financial Services Roundup: Market Talk

10 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

10 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

10 дек. 2025 г., 21:45 UTC

Приобретения, слияния, поглощения

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 дек. 2025 г., 21:33 UTC

Отчет

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 дек. 2025 г., 21:32 UTC

Отчет

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 дек. 2025 г., 21:28 UTC

Приобретения, слияния, поглощения

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 дек. 2025 г., 21:25 UTC

Отчет

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 дек. 2025 г., 21:18 UTC

Приобретения, слияния, поглощения

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 дек. 2025 г., 21:16 UTC

Отчет

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 дек. 2025 г., 21:15 UTC

Приобретения, слияния, поглощения

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 дек. 2025 г., 21:15 UTC

Отчет

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 дек. 2025 г., 21:14 UTC

Отчет

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 дек. 2025 г., 21:14 UTC

Отчет

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Сравнение c конкурентами

Изменение цены

Harvard Bioscience Inc Прогноз

Целевая цена

By TipRanks

163.16% рост

Прогноз на 12 месяцев

Средняя 2 USD  163.16%

Максимум 2 USD

Минимум 2 USD

Основано на мнении 1 аналитиков Wall Street, спрогнозировавших целевые цены для Harvard Bioscience Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

1 ratings

1

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

0.3 / 0.3401Поддержка и Сопротивление

Краткосрочная

Weak Bearish Evidence

Среднесрочная

No Evidence

Долгосрочная

No Evidence

Настроения

By Acuity

84 / 374Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat